Integrin Beta1 Market, By Type (AXT-108, C-16Y, CLT-28643, SAL-021 and Others), By Indication (Genetic Disorder, Dermatology, Cardiovascular and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI467721 | Publish Date: August 2023 | No. of Pages: 168

Global_Integrin_Beta1_Market Overview

Integrin beta-1 is also known as CD29, which is a cell surface receptor that is encoded by ITGB1 gene in humans. The integrins are associates with integrin alpha 1 and integrin alpha 2 to form integrin complexes that function as collagen receptor and forms dimer with integrin alpha 3 to form receptor for netrin 1 and reelin. In cardiac muscle and skeletal muscle, integrin beta-1D isoform is specially expressed and localizes to costameres and abnormal levels of integrin beta-1D cause limb girdle muscular dystrophy and polyneuropathy. Integrin family are membrane receptors involved in cell adhesion and recognition in various processes such as embryogenesis, hemostasis, tissue repair, immune response and metastatic diffusion of tumor cells. Integrin Beta-1 has three novel isoforms termed as integrin beta-1B, beta-1C, beta-1D. Integrin beta-1B isoforms to be dominant that it inhibits cell adhesion. The Integrin Beta1 Market accounted for US$ XX billion in 2020 and is estimated to be US$ XX billion by 2030 and is anticipated to register a CAGR of XX%.

Global_Integrin_Beta1_Market Dynamics

Increasing prevalence of Genetic disorder and cardiovascular diseases

Increasing prevalence of genetic disorder and cardiovascular diseases are expected to increase the demand for global Integrin Beta-1 market. Changing lifestyles and other activities is expected to boost the market for inhibitor demands during forecast period.

High Unmet Medical needs for patients

Patients are looking forward for advancement in drugs. Further, a large number of companies are now investing into this market to meet the needs of patients. Such companies are contributing for introduction of new drugs with better functionality into market.

However, side effects and fluctuation reimbursement policy by government such challenges might hamper growth of the global market to a certain extent.

Global_Integrin_Beta1_Market Segmentation

 

 

Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

The Global Integrin Beta 1 Market is segmented based on the type, indication, and region.

By Type, the Global Integrin Beta 1 Market   is segmented into AXT-108, C-16Y, CLT-28643, SAL-021 and Others. By indication, the market is segmented in Genetic Disorder, Dermatology, Cardiovascular, Others. By region, the Global Integrin Beta 1 Market   is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the worldwide leader in the integrin Beta 1 market in terms of revenue, due to the developed healthcare system and health awareness among people.

Regional Insights:

On region the global Integrin Beta 1 Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the market during forecast period due to developed and well-structured healthcare system. This region majorly focuses in the research field of cancer. Major key players are also in North America. Presence of large number of patients in the U.S. and Canada further contributes market growth. For instance, as per a 2018 report by the World Cancer Research Fund International, the prevalence of cancer in the U.S. is 352.2 per 100,000. As per the same report, Canada also has a high prevalence of cancer with 334 per 100,000.

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2030

Market Segmentation

By Type- AXT-108, C-16Y, CLT-28643, SAL-021 and Others.

By Indication– Genetic Disorder, Dermatology, Cardiovascular, Others.

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this study, has segmented the Global Integrin Beta 1 Market   is segmented based on the type, indication, and region.

 

Global Integrin Beta 1 Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global_Integrin_Beta1_Market Key Players

The key players operating in the global Integrin Beta 1 Market includes Avipero Ltd, Clanotech AB, Morphic Therapeutic Inc, Strykagen Corp, Valeant Pharmaceuticals International Inc.

Global_Integrin_Beta1_Market Company Profile

  • Strykagen Corp
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Avipero Ltd
  •  Clanotech AB
  •  Morphic Therapeutic Inc
  • Valeant Pharmaceuticals International IncBNTX Inc.

“*” marked represents similar segmentation in other categories in the respective section

Global_Integrin_Beta1_Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Integrin Beta 1 Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Type
      • Market Snippet, By Indication
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Integrin Beta 1 Market  , By Type, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • AXT-108
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • C-16Y
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • CLT-28643
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    •  SAL-021
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Other
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  6. Global Integrin Beta 1 Market , By Indication, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    •  Genetic Disorder
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Dermatology
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Cardiovascular
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  7. Global Integrin Beta 1 Market  , By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Indication, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Indication, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Indication, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Indication, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Indication, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  9. Company Profiles
  • Strykagen Corp
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Avipero Ltd
  •  Clanotech AB
  •  Morphic Therapeutic Inc
  • Valeant Pharmaceuticals International IncBNTX Inc.
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

 

FAQs

The Global Integrin Beta 1 Market is segmented based on the type, indication, and region.

Rising initiatives by government bodies and advancement in research & technology are the major factors driving growth of the global market

North America is expected to dominate the market during forecast period due to developed and well-structured healthcare system. This region majorly focus in the research field and further especially in cancer.

The key players operating in the global Integrin Beta 1 Market market includes Avipero Ltd, Clanotech AB, Morphic Therapeutic Inc, Strykagen Corp, Valeant Pharmaceuticals International Inc.